Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalised HIPEC with cytoreductive surgery for colorectal peritoneal metastases
ACTRN12624001230549Phase 3Not yet recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of mitomycin c, oxaliplatin and irinotecan in colorectal peritoneal metastases (CPM) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Peritoneal disease-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
mitomycin coxaliplatinirinotecan
03
Conditions
colorectal peritoneal metastases (CPM)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ACTRN12624001230549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001230549.